MINDACT Trial: Agendia's MammoPrint Test Identifies No-Chemo Candidates

By identifying the patients at low risk for recurrence, MammaPrint could spare more than 100,000 women with early-stage breast cancer worldwide from unnecessary chemotherapy, according to Agendia.